Skip to main content
SpringerLink
Log in

Pharmacokinetics of oral hydralazine in chronic heart failure

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The influence of various disease states, other than hypertension, on the pharmacokinetic behaviour of hydralazine is not completely known. In the present study the pharmacokinetics of oral hydralazine has been evaluated in 7 patients with severe, chronic heart failure, using 8 compensated hypertensives as controls. The pharmacokinetics was evaluated by measuring the plasma concentrations of hydralazine (“apparent” and “real” hydralazine) and hydralazine pyruvate hydrazone, and by assessing acetylator phenotype after a small dose of dapsone. The AUC (area under the plasma concentration curve) following a single, oral 50 mg dose was significantly larger in patients with chronic heart failure NYHA Class III–IV than in patients with essential hypertension without cardiac decompensation. A decreased rate of hepatic elimination of hydralazine is suggested as a major contributory factor to this finding.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chatterjee K, Parmley W (1977) The role of vasodilator therapy in heart failure. Prog Cardiovasc Dis 19: 301–325

    Google Scholar 

  2. Cohn JN, Franciosa JA (1977) Vasodilator therapy in cardiac failure. N Engl J Med 297: 27–31, 254–258

    Google Scholar 

  3. Chatterjee K, Parmley WW, Massie B, Greenberg B, Werner J, Klausner S, Norman A (1976) Oral hydralazine therapy for chronic refractory heart failure. Circulation 54: 879–883

    Google Scholar 

  4. Packer M, Meller J, Medina N, Gorlin R, Herman MV (1980) Hemodynamic evaluation of hydralazine dosage in refractory heart failure. Clin Pharmacol Ther 27: 337–346

    Google Scholar 

  5. Conradson T-B, Rydén L (1981) Sustained effect of hydralazine in long-term treatment of CHF. Acta Med Scand (Suppl) 652: 173–176

    Google Scholar 

  6. Mathey D, Hanrath P, Polster J, Whitte G, Montz R, Bleifeld W (1980) Acute and chronic effects of oral hydralazine on left ventricular pump function and renal hemodynamics in chronic left heart failure. Eur Heart J 1: 25–29

    Google Scholar 

  7. Packer M, Meller J, Medina, N, Gorlin R, Herman MV (1980) Dose requirements of hydralazine in patients with severe chronic congestive heart failure. Am J Cardiol 45: 655–660

    Google Scholar 

  8. Israili ZH, Dayton PG (1977) Metabolism of hydralazine. Drug Metab Rev 6: 283–305

    Google Scholar 

  9. Wagner J, Faigle JW, Imhof P, Liehr G (1977) Metabolism of hydralazine in man. Arzneim Forsch 27 (II): 2388–2395

    Google Scholar 

  10. Timbrell JA, Harland SJ, Facchini V (1980) Polymorfic acetylation of hydralazine. Clin Pharmacol Ther 28: 350–355

    Google Scholar 

  11. Reece PA, Stanley PE, Zacest R (1978) Interference in assays for hydralazine in humans by a major plasma metabolite, hydralazine pyruvic acid hydrazone. J Pharm Sci 67: 1151–1153

    Google Scholar 

  12. Ludden TM, McNay JL, Shepherd AMM, Lin MS (1982) Clinical pharmacokinetics of hydralazine. Clin Pharmacokinet 7: 185–205

    Google Scholar 

  13. Jack DB, Brechbühler S, Degen PH, Zbinden P, Riess W (1975) The determination of hydralazine in plasma by gasliquid chromatography. J Chromatogr 115: 87–92

    Google Scholar 

  14. Zak SB, Lukas G, Gilleran TG (1977) Plasma levels of real and “apparent” hydralazine in man and rat. Drug Metab Dispos 5: 116–121

    Google Scholar 

  15. Hanson A, Melander A, Wåhlin-Boll E (1981) Acetylator phenotyping: A comparison of the isoniazid and dapsone tests. Eur J Clin Pharmacol 20: 233–234

    Google Scholar 

  16. Tokola O, Pelkonen O, Karki NT, Luoma P, Kaltiala EH, Larmi TKI (1975) Hepatic drug-oxidizing enzyme systems and urinary D-glucaric acid excretion in patients with congestive heart failure. Br J Clin Pharmacol 2: 429–436

    Google Scholar 

  17. Cumming JF, Mannering GJ (1970) Effect of phenobarbital administration on the oxygen requirement for hexobarbital metabolism in the isolated, perfused rat liver and in the intact rat. Biochem Pharmacol 19: 973–978

    Google Scholar 

  18. Dunn GD, Hayes P, Breen KJ, Schenker S (1973) The liver in congestive heart failure: A review. Am J Med Sci 265: 174–189

    Google Scholar 

  19. Lesser JM, Israili ZH, Davies DC, Dayton PG (1974) Metabolism and disposition of hydralazine-14C, in man and dog. Drug Metab Dispos 2: 351–360

    Google Scholar 

  20. Reidenberg MM, Drayer D, de Marco AL, Bello CT (1973) Hydralazine elimination in man. Clin Pharmacol Ther 14: 970–977

    Google Scholar 

  21. Talseth T (1976) Studies on hydralazine I: Serum concentrations of hydralazine in man after a single dose and at steady-state. Eur J Clin Pharmacol 10: 183–187

    Google Scholar 

  22. Zak SB, Gilleran TG, Karliner J, Lukas G (1974) Identification of two new metabolites of hydralazine from human urine. J Med Chem 17: 381–382

    Google Scholar 

  23. Shepherd AMM, Ludden TM, Haegele KD, Talseth T, McNay JL (1979) Pharmacokinetics of hydralazine, apparent hydralazine and hydralazine pyruvic acid hydrazone in humans. Res Commun Chem Pathol Pharmacol 26: 129–144

    Google Scholar 

  24. Henningsen NC, Hanson A, Wernersson B (1982) Single versus multiple daily administration of hydralazine in the maintenance treatment of hypertension — Clinical and pharmacokinetic aspects. Acta Med Scand 211: 179–185

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Clinical Chemistry, Section of Toxicology, and Medicine, Section of Cardiology, Malmö General Hospital, Malmö, Sweden

    A. Hanson, B. W. Johansson, B. Wernersson & L. Å. Wåhlander

  2. Medical Department, Ciba-Geigy Läkemedel AB, Västra Frölunda, Sweden

    A. Hanson, B. W. Johansson, B. Wernersson & L. Å. Wåhlander

Authors
  1. A. Hanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. W. Johansson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Wernersson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Å. Wåhlander
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hanson, A., Johansson, B.W., Wernersson, B. et al. Pharmacokinetics of oral hydralazine in chronic heart failure. Eur J Clin Pharmacol 25, 467–473 (1983). https://doi.org/10.1007/BF00542113

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00542113

Key words

Search

Navigation